National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Antimicrobial resistance especially in Pseudomonas spp. is an increasing problem across the world and therefore, its trend of antimicrobial resistance requires to be studied. The objective of current study was to determine the prevalence of Pseudomonas aeruginosa in various clinical samples collected during study and to analyze the antibiotic susceptibility patterns of various drugs against it. During the study, a total of 231 P. aeruginosa isolated from 870 clinical samples like brancho-alveolar fluid (BAL), blood, endotracheal secretion, Foleys tip culture, pleurineral flurineid, pus, spurineturinem, sputum, swab curinelturinere, urine and wound. Antibiotic susceptibility testing were carried out according to the recommendations of Clinical Laboratory Standards Institute (CLSI) guidelines. The highest number of Pseudomonas infections was found in urine, followed by endotracheal, blood, BAL, spurineturinem, wound, pus, foley’s tip, pleurineral flurineid, sputum and swab. Tobracef was the most active drug tested (82.25% susceptible), followed by pipercillin+tazobactam (74.89% susceptible), cefoperazone+sulbactam (67.10% susceptible), meropenem (64.94% susceptible) and ceftazidime (60.17% susceptible). From the present study, it appears that lower respiratory tract infection was the most common hospital acquired infection caused by multidrug resistant (MDR) P. aeruginosa. Moderate rates of drug resistance among P. aeruginosa isolates were observed against ceftazidime and meropenem. This pattern of resistance indicates probable overuse of broad-spectrum antibiotics without the having knowledge of sensitivity patterns of drugs. So there is a continuous need of conduction of surveillance programmes to recommend appropriate therapy to patients. Moreover, our data also demonstrated that Tobracef has enhanced in-vitro antibacterial activity and exhibited 17> % superiority over meropenem. Therefore, it can be a better choice to treat the infections caused by multi-drug resistant P. aeruginosa.
Citations |
 |
 |
 |
 |
